Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C13H9NOSe |
| Molecular Weight | 274.18 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C1N([Se]C2=C1C=CC=C2)C3=CC=CC=C3
InChI
InChIKey=DYEFUKCXAQOFHX-UHFFFAOYSA-N
InChI=1S/C13H9NOSe/c15-13-11-8-4-5-9-12(11)16-14(13)10-6-2-1-3-7-10/h1-9H
| Molecular Formula | C13H9NOSe |
| Molecular Weight | 274.18 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Ebselen is a small molecule mimic and inducer of glutathione peroxidase activity and possesses antioxidant and anti-inflammatory properties. This drug has been investigated in phase II clinical trials for the treatment of Meniere's disease, bipolar disorder and in the prevention of hearing loss. Besides, experiments on mice have shown that ZIKV infection could be on the list for potential use of ebselen. It alleviates testicular pathology in mice with Zika virus infection and prevents its sexual transmission. Ebselen has various mechanisms of action. It binds to the N-terminal domain of soluble epoxide hydrolase and chemically reacts with the enzyme to quickly and irreversibly inhibit one of the enzymes' activity: phosphatase (Nterm-phos). Besides, ebselen inhibits inositol monophosphatase and thus exhibits lithium-like on human central nervous system (CNS) function. In addition, ebselen inhibits the G4 isoform of acetylcholinesterase. It is a well-known relationship between the cholinergic system and learning, memory and other common cognitive processes, thus ebselen can be studied for the treatment of memory impairment diseases.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P34913|||Q9HBJ2 Gene ID: 2053.0 Gene Symbol: EPHX2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/23219563 |
550.0 nM [Ki] | ||
Target ID: P22303|||Q53F46 Gene ID: 43.0 Gene Symbol: ACHE Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/29405440 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
|||
| Preventing | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
30.3 ng/mL |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
EBSELEN plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: FASTED |
|
67.5 ng/mL |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
EBSELEN plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: FASTED |
|
70.3 ng/mL |
800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered: |
EBSELEN plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: FASTED |
|
83.4 ng/mL |
1600 mg single, oral dose: 1600 mg route of administration: Oral experiment type: SINGLE co-administered: |
EBSELEN plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
546.31 ng × h/mL |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
EBSELEN plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: FASTED |
|
883.15 ng × h/mL |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
EBSELEN plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: FASTED |
|
710.1 ng × h/mL |
800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered: |
EBSELEN plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: FASTED |
|
992.64 ng × h/mL |
1600 mg single, oral dose: 1600 mg route of administration: Oral experiment type: SINGLE co-administered: |
EBSELEN plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
6.42 h |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
EBSELEN plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: FASTED |
|
12.1 h |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
EBSELEN plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: FASTED |
|
14.4 h |
800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered: |
EBSELEN plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: FASTED |
|
16.7 h |
1600 mg single, oral dose: 1600 mg route of administration: Oral experiment type: SINGLE co-administered: |
EBSELEN plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: FASTED |
PubMed
| Title | Date | PubMed |
|---|---|---|
| The seleno-organic compound ebselen impairs mitochondrial physiology and induces cell death in AR42J cells. | 2014-09-17 |
|
| Glutathione peroxidase mimic ebselen improves glucose-stimulated insulin secretion in murine islets. | 2014-01-10 |
|
| Antimalarial screening via large-scale purification of Plasmodium falciparum Ca2+-ATPase 6 and in vitro studies. | 2013-11 |
|
| In vitro glutathione peroxidase mimicry of ebselen is linked to its oxidation of critical thiols on key cerebral suphydryl proteins - A novel component of its GPx-mimic antioxidant mechanism emerging from its thiol-modulated toxicology and pharmacology. | 2013-10-25 |
|
| Interrogating a hexokinase-selected small-molecule library for inhibitors of Plasmodium falciparum hexokinase. | 2013-08 |
|
| Ebselen reduces the toxicity of mechlorethamine in A-431 cells via inhibition of apoptosis. | 2013-06 |
|
| Development of an HTS assay for EPHX2 phosphatase activity and screening of nontargeted libraries. | 2013-03-01 |
|
| Mitochondrial electron transfer chain complexes inhibition by different organochalcogens. | 2013-02 |
|
| Ebselen reduces hyperglycemia temporarily-induced by diazinon: a compound with insulin-mimetic properties. | 2012-05-30 |
|
| The monoamine oxidase A inhibitor clorgyline is a broad-spectrum inhibitor of fungal ABC and MFS transporter efflux pump activities which reverses the azole resistance of Candida albicans and Candida glabrata clinical isolates. | 2012-03 |
|
| A superoxide anion-scavenger, 1,3-selenazolidin-4-one suppresses serum deprivation-induced apoptosis in PC12 cells by activating MAP kinase. | 2011-12-15 |
|
| 3-(2,6-dimethylphenyl)-2-selenoxo-1,3-thiazolidin-4-one suppresses hydrogen peroxide-induced cytotoxicity on PC12 cells via activation of MAPK. | 2011-12 |
|
| Selenoprotein-dependent up-regulation of hematopoietic prostaglandin D2 synthase in macrophages is mediated through the activation of peroxisome proliferator-activated receptor (PPAR) gamma. | 2011-08-05 |
|
| Methylmercury-induced alterations in astrocyte functions are attenuated by ebselen. | 2011-06 |
|
| TGF-β regulates Nox4, MnSOD and catalase expression, and IL-6 release in airway smooth muscle cells. | 2011-02 |
|
| Reactive oxygen species, Ki-Ras, and mitochondrial superoxide dismutase cooperate in nerve growth factor-induced differentiation of PC12 cells. | 2010-07-30 |
|
| A cell protection screen reveals potent inhibitors of multiple stages of the hepatitis C virus life cycle. | 2010-02-23 |
|
| Mitochondria-derived reactive oxygen species mediate heme oxygenase-1 expression in sheared endothelial cells. | 2009-04 |
|
| The redox state of glutathione regulates the hypoxic induction of HIF-1. | 2009-03-15 |
|
| The protective mechanism of antioxidants in cadmium-induced ototoxicity in vitro and in vivo. | 2008-07 |
|
| Effects of poly(ADP-ribose) polymerase inhibition in bladder damage caused by cyclophosphamide in rats. | 2008-03 |
|
| Functional involvement of PHOSPHO1 in matrix vesicle-mediated skeletal mineralization. | 2007-04 |
|
| Cardioprotective effects of subcutaneous ebselen against daunorubicin-induced cardiomyopathy in rats. | 2006-12 |
|
| Up-regulation of heme oxygenase provides vascular protection in an animal model of diabetes through its antioxidant and antiapoptotic effects. | 2006-12 |
|
| Oral pretreatment with ebselen enhances heat shock protein 72 expression and reduces myocardial infarct size. | 2006-11 |
|
| Oxidative stress induces ADAM9 protein expression in human prostate cancer cells. | 2006-10-01 |
|
| Small-molecule screening identifies the selanazal drug ebselen as a potent inhibitor of DMT1-mediated iron uptake. | 2006-09 |
|
| Enhancement of tumor invasion depends on transdifferentiation of skin fibroblasts mediated by reactive oxygen species. | 2006-07-01 |
|
| Impairment of mitochondrial anti-oxidant defence in SOD1-related motor neuron injury and amelioration by ebselen. | 2006-07 |
|
| Ebselen attenuates haloperidol-induced orofacial dyskinesia and oxidative stress in rat brain. | 2005-07 |
|
| Azaanalogues of ebselen as antimicrobial and antiviral agents: synthesis and properties. | 2004-11 |
|
| Dimethyl sulfoxide and ebselen prevent convulsions induced by 5-aminolevulinic acid. | 2004-10 |
|
| Interaction of selenium compounds with zinc finger proteins involved in DNA repair. | 2004-08 |
|
| Renal and hepatic ALA-D activity and selected oxidative stress parameters of rats exposed to inorganic mercury and organoselenium compounds. | 2004-01 |
|
| Functionalized alkyl and aryl diselenides as antimicrobial and antiviral agents: synthesis and properties. | 2003-12 |
|
| Selenium-containing compounds attenuate peroxynitrite-mediated NF-kappaB and AP-1 activation and interleukin-8 gene and protein expression in human leukocytes. | 2003-11-01 |
|
| Hypoxia and stretch regulate intercellular communication in vascular smooth muscle cells through reactive oxygen species formation. | 2003-10-01 |
|
| An inducible nitric oxide synthase-luciferase reporter system for in vivo testing of anti-inflammatory compounds in transgenic mice. | 2003-06-15 |
|
| Activation of matrix metalloproteinase-2 by overexpression of manganese superoxide dismutase in human breast cancer MCF-7 cells involves reactive oxygen species. | 2002-06-07 |
|
| Anti-oxidant ebselen causes the resolution of experimentally induced hepatic fibrosis in rats. | 2001-11 |
|
| Inhibition of ebselen on aflatoxin B(1)-induced hepatocarcinogenesis in Fischer 344 rats. | 2000-12 |
|
| Transcriptional and posttranscriptional regulation of endothelial nitric oxide synthase expression by hydrogen peroxide. | 2000-02-18 |
|
| Cellular factors as alternative targets for inhibition of HIV-1. | 1997-02 |
|
| Molecular actions of ebselen--an antiinflammatory antioxidant. | 1995-10 |
|
| Interaction of ebselen with glutathione S-transferase and papain in vitro. | 1994-03-15 |
|
| PZ-51 (Ebselen) in vivo protection against adriamycin-induced mouse cardiac and hepatic lipid peroxidation and toxicity. | 1992-08-18 |
|
| Effects of the seleno-organic substance Ebselen in two different models of acute pancreatitis. | 1991-05 |
Patents
Sample Use Guides
Bipolar Disorder: ebselen capsules each containing 200mg taken orally twice a day for 3 weeks
Meniere's Disease: 200, 400 or 600 mg of drug bid po x 21d
hearing loss: 400 mg twice daily
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/29405440
ebselen at concentrations equal or higher than 10 µM inhibited the activity of cortical and hippocampal G4/acethylcholinesterase (AChE), but not G1/AChE isoform.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 08:48:06 GMT 2025
by
admin
on
Wed Apr 02 08:48:06 GMT 2025
|
| Record UNII |
40X2P7DPGH
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C1323
Created by
admin on Wed Apr 02 08:48:06 GMT 2025 , Edited by admin on Wed Apr 02 08:48:06 GMT 2025
|
||
|
NCI_THESAURUS |
C275
Created by
admin on Wed Apr 02 08:48:06 GMT 2025 , Edited by admin on Wed Apr 02 08:48:06 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C65503
Created by
admin on Wed Apr 02 08:48:06 GMT 2025 , Edited by admin on Wed Apr 02 08:48:06 GMT 2025
|
PRIMARY | |||
|
100000080483
Created by
admin on Wed Apr 02 08:48:06 GMT 2025 , Edited by admin on Wed Apr 02 08:48:06 GMT 2025
|
PRIMARY | |||
|
77543
Created by
admin on Wed Apr 02 08:48:06 GMT 2025 , Edited by admin on Wed Apr 02 08:48:06 GMT 2025
|
PRIMARY | |||
|
40X2P7DPGH
Created by
admin on Wed Apr 02 08:48:06 GMT 2025 , Edited by admin on Wed Apr 02 08:48:06 GMT 2025
|
PRIMARY | |||
|
60940-34-3
Created by
admin on Wed Apr 02 08:48:06 GMT 2025 , Edited by admin on Wed Apr 02 08:48:06 GMT 2025
|
PRIMARY | |||
|
DTXSID7045150
Created by
admin on Wed Apr 02 08:48:06 GMT 2025 , Edited by admin on Wed Apr 02 08:48:06 GMT 2025
|
PRIMARY | |||
|
639762
Created by
admin on Wed Apr 02 08:48:06 GMT 2025 , Edited by admin on Wed Apr 02 08:48:06 GMT 2025
|
PRIMARY | |||
|
757883
Created by
admin on Wed Apr 02 08:48:06 GMT 2025 , Edited by admin on Wed Apr 02 08:48:06 GMT 2025
|
PRIMARY | |||
|
C042986
Created by
admin on Wed Apr 02 08:48:06 GMT 2025 , Edited by admin on Wed Apr 02 08:48:06 GMT 2025
|
PRIMARY | |||
|
5475
Created by
admin on Wed Apr 02 08:48:06 GMT 2025 , Edited by admin on Wed Apr 02 08:48:06 GMT 2025
|
PRIMARY | |||
|
EBSELEN
Created by
admin on Wed Apr 02 08:48:06 GMT 2025 , Edited by admin on Wed Apr 02 08:48:06 GMT 2025
|
PRIMARY | |||
|
DB12610
Created by
admin on Wed Apr 02 08:48:06 GMT 2025 , Edited by admin on Wed Apr 02 08:48:06 GMT 2025
|
PRIMARY | |||
|
SUB06439MIG
Created by
admin on Wed Apr 02 08:48:06 GMT 2025 , Edited by admin on Wed Apr 02 08:48:06 GMT 2025
|
PRIMARY | |||
|
m4803
Created by
admin on Wed Apr 02 08:48:06 GMT 2025 , Edited by admin on Wed Apr 02 08:48:06 GMT 2025
|
PRIMARY | Merck Index | ||
|
3194
Created by
admin on Wed Apr 02 08:48:06 GMT 2025 , Edited by admin on Wed Apr 02 08:48:06 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |